Home About us Contact
|
Home About us Contact | ||
|
|
||
Inhibition Constant (inhibition + constant)
Selected AbstractsInhibition of Porphyromonas gingivalis proteinases (gingipains) by chlorhexidine: synergistic effect of Zn(II)MOLECULAR ORAL MICROBIOLOGY, Issue 4 2006C. A. Cronan Background/aims:, Gingipains, proteolytic enzymes produced by the periodontal pathogen Porphyromonas gingivalis, are regarded as virulence factors in the pathogenesis of periodontitis. Inhibition of gingipain activity therefore may have therapeutic potential, and it has been suggested that chlorhexidine may inhibit the activities of these enzymes. The purposes of the present study were to examine systematically the inhibitory effects of chlorhexidine on three purified gingipains and to determine the effect of Zn(II) on chlorhexidine inhibition. Methods:, The activities of lys-gingipain (Kgp) and two forms of arg-gingipain (RgpB and HRgpA) were measured in the presence of varying concentrations of chlorhexidine and with chlorhexidine supplemented with Zn(II). Inhibition constants (Ki's) were determined for chlorhexidine alone and in the presence of Zn(II). Fractional inhibitory constant indices were calculated to assess the synergy of the chlorhexidine,Zn(II) inhibition. Results:, RgpB, HRgpA, and Kgp were all inhibited by chlorhexidine with Ki's in the micromolar range. For RgpB and HRgpA, the inhibitory effects of chlorhexidine were enhanced 3,30-fold by Zn(II). The chlorhexidine,Zn(II) interaction was synergistic for inhibition of HRgpA and RgpB. For Kgp, the effect of Zn(II) on chlorhexidine inhibition was antagonistic. Conclusions:, Chlorhexidine is an effective inhibitor of gingipains, and the inhibition of R-gingipains is enhanced by Zn(II). A mixture of chlorhexidine and Zn(II) may be useful as an adjunct in the treatment of periodontitis and in the post-treatment maintenance of periodontitis patients. [source] A Novel Synthesis of Highly Substituted Perhydropyrrolizines, Perhydroindolizines, and Pyrrolidines: Inhibition of the Peptidyl-Prolyl cis/trans Isomerase (PPIase) Pin1HELVETICA CHIMICA ACTA, Issue 2 2007Romain Siegrist Abstract In this paper, we describe the synthesis and biological evaluation of highly substituted perhydropyrrolizines that inhibit the peptidyl-prolyl cis/trans isomerase (PPIase) Pin1, an oncogenic target. The enzyme selectively catalyzes the cis/trans isomerization of peptide bonds between a phosphorylated serine or threonine, and proline, thereby inducing a conformational change. Such structural modifications play an important role in many cellular events, such as cell-cycle progression, transcriptional regulation, RNA processing, as well as cell proliferation and differentiation. Based on computer modeling (Fig.,2), the new perhydropyrrolizinone derivatives (,)- 1a,b, decorated with two substituents, were selected and synthesized (Schemes,1,3). While enzymatic assays showed no biological activity, 15N,1H-HSQC-NMR spectroscopy revealed that (,)- 1a,b bind to the WW recognition domain of Pin1, apparently in a mode that does not inhibit PPIase activity. To enforce complexation into the larger active site rather than into the tighter WW domain of Pin1 and to enhance the overall binding affinity, we designed a perhydropyrrolizine scaffold substituted with additional aromatic residues (Fig.,5). A novel, straightforward synthesis towards this class of compounds was developed (Schemes,4 and 5), and the racemic compounds (±)- 22a,22d were found to inhibit Pin1 with Ki values (Ki,=,inhibition constant) in the micromolar range (Table,2). To further enhance the potency of these inhibitors, the optically pure ligands (+)- 22a and (+)- 33b,c were prepared (Schemes,6 and 7) and shown to inhibit Pin1 with Ki values down to the single-digit micromolar range. According to 15N,1H-HSQC-NMR spectroscopy and enzymatic activity assays, binding occurs at both the WW domain and the active site of Pin1. Furthermore, the new synthetic protocol towards perhydropyrrolizines was extended to the preparation of highly substituted perhydroindolizine ((±)- 43; Scheme,8) and pyrrolidine ((±)- 48a,b; Scheme,9) derivatives, illustrating a new, potentially general access to these highly substituted heterocycles. [source] Inhibitory activity of brown algal phlorotannins against hyaluronidaseINTERNATIONAL JOURNAL OF FOOD SCIENCE & TECHNOLOGY, Issue 6 2002Toshiyuki Shibata The inhibitory effect of brown algal phlorotannins on hyaluronidase was evaluated by an in vitro assay. Crude phlorotannins from the brown algae Eisenia bicyclis and Ecklonia kurome had a stronger inhibitory effect than well-known inhibitors such as catechins and sodium cromoglycate. IC50 values of the following six phlorotannins: phloroglucinol, an unknown tetramer, eckol (a trimer), phlorofucofuroeckol A (a pentamer), dieckol and 8,8,-bieckol (hexamers), were 280, 650, >800, 140, 120 and 40 ,M, respectively. The IC50 of catechin, epigallocatechin gallate and sodium cromoglycate was 620, 190 and 270 ,M, respectively. 8,8,-Bieckol, the strongest HAase inhibitor in this study, acted as a competitive inhibitor with an inhibition constant (Ki) of 35 ,M. Acetylation of the phlorotannins markedly decreased their inhibitory potency. [source] Kinetics and thermodynamics of glucoamylase inhibition by lactate during fermentable sugar production from food wasteJOURNAL OF CHEMICAL TECHNOLOGY & BIOTECHNOLOGY, Issue 5 2010Xiao Qiang Wang Abstract BACKGROUND: Glucoamylase hydrolysis is a key step in the bioconversion of food waste with complicated composition. This work investigated the effect of lactate on glucoamylase from Aspergillus niger UV-60, and inhibition mechanisms of glucoamylase by lactate during food waste hydrolysis. RESULTS: For 125 min hydrolysis of food waste (10%, dry basis), reducing sugars produced in the absence of lactate were 15%, 26% and 56% more than those produced in the presence of 24 g L,1 lactate at 60, 50 and 40 °C, respectively. Kinetic study showed that the type of glucoamylase inhibition by lactate was competitive, and Km (Michaelis-Menten constent), Vmax (maximum initial velocity), KI (inhibition constant) were 103.2 g L,1, 5.0 g L,1 min,1, 100.6 g L,1, respectively, for food waste hydrolysis at 60 °C and pH 4.6. Lactate also accelerated glucoamylase denaturation significantly. Activation energy of denaturation without inhibitor was 61% greater than that of denaturation with inhibitor (24 g L,1 lactate). Half-lives (t1/2) without inhibitor were 7.6, 2.7, 2.6, 1.7 and 1.2 times longer than those with inhibitor at temperature 40, 45, 50, 55 and 60 °C, respectively. CONCLUSION: These results are helpful to process optimization of saccharification and bioconversion of food waste. Copyright © 2010 Society of Chemical Industry [source] Biodegradation kinetics of benzene, methyl tert -butyl ether, and toluene as a substrate under various substrate concentrationsJOURNAL OF CHEMICAL TECHNOLOGY & BIOTECHNOLOGY, Issue 1 2007Chi-Wen Lin Abstract Owing to the complexity of conventional methods and shortcomings in determining kinetic parameters, a convenient approach using the nonlinear regression analysis of Monod or Haldane type nonlinear equations is presented. This method has been proven to provide accurate estimates of kinetic parameters. The major work in this study consisted of the testing of aromatic compound-degrading cultures in batch experiments for the biodegradation of benzene, methyl tert -butyl ether (MTBE), and toluene. Additionally, batch growth data of three pure cultures (i.e., Pseudomonas aeruginosa YAMT421, Ralstonia sp. YABE411 and Pseudomonas sp. YATO411) isolated from an industrial petrochemical wastewater treatment plant under aerobic conditions were assessed with the nonlinear regression technique and with a trial-and-error procedure to determine the kinetic parameters. The growth rates of MTBE-, benzene-, and toluene-degrading cultures on MTBE, benzene, and toluene were significant. Monod's model was a good fit for MTBE, benzene and toluene at low substrate concentrations. In contrast, Haldane's equation fitted well in substrate inhibition concentration. Monod and Haldane's expressions were found to describe the results of these experiments well, with fitting values higher than 98%. The kinetic parameters, including a maximum specific growth rate (µm), a half-saturation constant (Ks), and an inhibition constant (Ki), were given. Copyright © 2007 Society of Chemical Industry [source] Purification and Characterization of Low Molecular Weight Kininogen from Pig PlasmaJOURNAL OF FOOD SCIENCE, Issue 1 2000J.-J. Lee ABSTRACT: A cysteine proteinase inhibitor from pig plasma with a molecular weight (MW) of 55 kDa, purified to electrophoretical homogeneity, inhibited ,- and m -calpains, cathepsins B, L, and L-like, and papain, but did not inhibit trypsin, ,-chymotrypsin, and cathepsin D. The purified inhibitor was stable at pH 3.0 to 10.5. The amounts for 50% inactivation (ID50) of papain, cathepsins B, L, and L-like, ,- and m-calpains were 10.55, 12.91, 2.18, 2.18, 30.91, and 29.27 nM, while the inhibition constant (Ki) for cathepsins B, L, L-like, and X, and ,- and m-calpains were 1.1, 0.64, 63.33, 8.19, 26, and 23.57 nM, respectively. It could inhibit the proteolysis of mackerel myosin heavy chain caused by purified cathepsin L-like at 55 °C. Based on the MW, stability and specificity, it was identified as L-kininogen. [source] Extrapolating in vitro metabolic interactions to isolated perfused liver: Predictions of metabolic interactions between R -bufuralol, bunitrolol, and debrisoquineJOURNAL OF PHARMACEUTICAL SCIENCES, Issue 10 2010Sami Haddad Abstract Drug,drug interactions (DDIs) are a great concern to the selection of new drug candidates. While in vitro screening assays for DDI are a routine procedure in preclinical research, their interpretation and relevance for the in vivo situation still represent a major challenge. The objective of the present study was to develop a novel mechanistic modeling approach to quantitatively predict DDI solely based upon in vitro data. The overall strategy consisted of developing a model of the liver with physiological details on three subcompartments: the sinusoidal space, the space of Disse, and the cellular matrix. The substrate and inhibitor concentrations available to the metabolizing enzyme were modeled with respect to time and were used to relate the in vitro inhibition constant (Ki) to the in vivo situation. The development of the liver model was supported by experimental studies in a stepwise fashion: (i) characterizing the interactions between the three selected drugs (R -bufuralol (BUF), bunitrolol (BUN), and debrisoquine (DBQ)) in microsomal incubations, (ii) modeling DDI based on binary mixtures model for all the possible pairs of interactions (BUF,BUN, BUF,DBQ, BUN,DBQ) describing a mutual competitive inhibition between the compounds, (iii) incorporating in the binary mixtures model the related constants determined in vitro for the inhibition, metabolism, transport, and partition coefficients of each compound, and (iv) validating the overall liver model for the prediction of the perfusate kinetics of each drug determined in isolated perfused rat liver (IPRL) for the single and paired compounds. Results from microsomal coincubations showed that competitive inhibition was the mechanism of interactions between all three compounds, as expected since those compounds are all substrates of rat CYP2D2. For each drug, the Ki values estimated were similar to their Km values for CYP2D2 indicative of a competition for the same substrate-binding site. Comparison of the performance between the novel liver physiologically based pharmacokinetic (PBPK) model and published empirical models in simulating the perfusate concentration,time profile was based on the area under the curve (AUC) and the shape of the curve of the perfusate time course. The present liver PBPK model was able to quantitatively predict the metabolic interactions determined during the perfusions of mixtures of BUF,DBQ and BUN,DBQ. However, a lower degree of accuracy was obtained for the mixtures of BUF,BUN, potentially due to some interindividual variability in the relative proportion of CYP2D1 and CYP2D2 isoenzymes, both involved in BUF metabolism. Overall, in this metabolic interaction prediction exercise, the PBPK model clearly showed to be the best predictor of perfusate kinetics compared to more empirical models. The present study demonstrated the potential of the mechanistic liver model to enable predictions of metabolic DDI under in vivo condition solely from in vitro information. © 2010 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 99:4406,4426, 2010 [source] Ortho Effects in Quantitative Structure Activity Relationships for Lipase Inhibition by Aryl CarbamatesMOLECULAR INFORMATICS, Issue 8 2003Gialih Lin Abstract Ortho -substituted phenyl- N -butyl carbamates (1,11) are synthesized and evaluated for their inhibition effects on Pseudomonas species lipase. Carbamates 1,11 are characterized as pseudo-substrate inhibitors of the enzyme. The logarithms of dissociation constant (Ki), carbamylation constant (k2), and bimolecular inhibition constant (ki) multiply linearly correlate with Hammett substituent constant (,), Taft-Kutter-Hansch ortho steric constant (ES), and Swan-Lupton field constant (F). For ,logKi -, logk2 -, and logki -correlations, values of ,, ,, f, ,XR are 0.2, ,0.06, ,1.7, 0.8; 0.0, 0.0, 1.0, ,0.07; and ,1.8, 7, 0.6, 5; respectively. The enzyme inhibition mechanism is composed of four steps: 1) the first step which is protonation of carbamates 1,11, 2) the second step (Ki1) which involves in the proton 1,3-shift of protonated carbamates 1,11 then the pseudo- trans to cis conformational change, 3) the third step (Ki2) which is formation of a negative charged enzyme-inhibitor tetrahedral intermediate, and 4) the fourth step (k2) which is the carbamylation step. The former three steps are likely composed of the Ki step. There is little ortho steric enhancement effect in the Ki step. From cross-interaction correlations, distance between carbamate and phenyl substituents in transition state for the Ki step is relatively short due to a large ,XR value of 7. The k2 step is insensitive to ortho steric effect. The k2 step involves in departure of leaving group, substituted phenol in which is protonated from the proton 1,3-shift but not from the active site histidine of the enzyme. From cross-interaction correlations, the distance between carbamate and phenyl substituents in transition state for the k2 step is relatively long due to a small ,XR value of 0.6. [source] Prediction of herb,drug metabolic interactions: a simulation studyPHYTOTHERAPY RESEARCH, Issue 6 2005Shufeng Zhou Abstract In vitro and in vivo studies have indicated that the induction or inhibition of cytochrome P450 (CYP) is one of the major mechanisms for some clinically important pharmacokinetic herb,drug interactions. An attempt was made to simulate the effects of herbal preparation with single or multiple CYP-inhibiting constituents on the area of the plasma concentration-time curve (AUC) of coadministered drug that was either a low clearance drug by intravenous (i.v.) injection or a high clearance drug by oral route. Our simulation studies indicated that the expected increase (Rc) in the AUC of the coadministered drug by inhibiting herbal constituent(s) was dependent on the route of administration. For low clearance drug by i.v. injection, Rc was generally determined by inhibition constant (Ki), unbound inhibitor concentration ([I]), hepatic fraction (fh), number of inhibitory herbal constituents (n) and metabolic pathway fraction in hepatic metabolism (fm), while Rc for a high clearance drug by oral route, Rc was determined by Ki, [I], n and fm. By varying these parameters, Rc changed accordingly. It appeared likely to predict a herb,drug metabolic interaction, if the inhibiting herbal constituents could be quantitatively determined. However, many herb- and drug-related factors may cause difficulties with the prediction, and thus in vivo animal and human studies are always necessary. Copyright © 2005 John Wiley & Sons, Ltd. [source] Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavirPROTEIN SCIENCE, Issue 9 2008Klára Grantz, ková Abstract Lopinavir (LPV) is a second-generation HIV protease inhibitor (PI) designed to overcome resistance development in patients undergoing long-term antiviral therapy. The mutation of isoleucine at position 47 of the HIV protease (PR) to alanine is associated with a high level of resistance to LPV. In this study, we show that recombinant PR containing a single I47A substitution has the inhibition constant (Ki) value for lopinavir by two orders of magnitude higher than for the wild-type PR. The addition of the I47A substitution to the background of a multiply mutated PR species from an AIDS patient showed a three-order-of-magnitude increase in Ki in vitro relative to the patient PR without the I47A mutation. The crystal structure of I47A PR in complex with LPV showed the loss of van der Waals interactions in the S2/S2, subsites. This is caused by the loss of three side-chain methyl groups due to the I47A substitution and by structural changes in the A47 main chain that lead to structural changes in the flap antiparallel ,-strand. Furthermore, we analyzed possible interaction of the I47A mutation with secondary mutations V32I and I54V. We show that both mutations in combination with I47A synergistically increase the relative resistance to LPV in vitro. The crystal structure of the I47A/I54V PR double mutant in complex with LPV shows that the I54V mutation leads to a compaction of the flap, and molecular modeling suggests that the introduction of the I54V mutation indirectly affects the strain of the bound inhibitor in the PR binding cleft. [source] Energy-dependent degradation: Linkage between ClpX-catalyzed nucleotide hydrolysis and protein-substrate processingPROTEIN SCIENCE, Issue 5 2003Randall E. Burton Abstract ClpX requires ATP to unfold protein substrates and translocate them into the proteolytic chamber of ClpP for degradation. The steady-state parameters for hydrolysis of ATP and ATP,S by ClpX were measured with different protein partners and the kinetics of degradation of ssrA-tagged substrates were determined with both nucleotides. ClpX hydrolyzed ATP,S to ADP and thiophosphate at a rate (6/min) significantly slower than ATP hydrolysis (140/min), but the hydrolysis of both nucleotides was increased by ssrA-tagged substrates and decreased by ClpP. KM and kcat for hydrolysis of ATP and ATP,S were linearly correlated over a 200-fold range, suggesting that protein partners largely affect kcat rather than nucleotide binding, indicating that most bound ATP leaves the enzyme by hydrolysis rather than dissociation, and placing an upper limit of ,15 ,M on KD for both nucleotides. Competition studies with ClpX and fluorescently labeled ADP gave inhibition constants for ATP,S (,2 ,M) and ADP (,3 ,M) under the reaction conditions used for steady-state kinetics. In the absence of Mg2+, where hydrolysis does not occur, the inhibition constant for ATP (,55 ,M) was weaker but very similar to the value for ATP,S (,45 ,M). Compared with ATP, ATP,S supported slow but roughly comparable rates of ClpXP degradation for two Arc-ssrA substrates and denatured GFP-ssrA, but not of native GFP-ssrA. These results show that the processing of protein substrates by ClpX is closely coupled to the maximum rate of nucleotide hydrolysis. [source] Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancerBRITISH JOURNAL OF CLINICAL PHARMACOLOGY, Issue 5 2010Stijn L. W. Koolen WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT , Docetaxel is an approved drug for the treatment of cancer of various primary origins. , An oral docetaxel regimen is warranted because of patient convenience and the opportunity to investigate more schedule intensive treatment regimens. , Co-administration of ritonavir significantly enhanced the apparent oral bioavailability of docetaxel. WHAT THIS STUDY ADDS , This study demonstrates that ritonavir increased the absorption of docetaxel after oral administration. , Furthermore, we showed that the clearance of docetaxel was inhibited in a concentration dependent manner. , The developed model will be used for further development of an oral docetaxel regimen. AIM Docetaxel has a low oral bioavailability due to affinity for P-glycoprotein and cytochrome P450 (CYP) 3A4 enzymes. Inhibition of the CYP3A4 enzymes by ritonavir resulted in increased oral bioavailability. The aim of this study was to develop a population pharmacokinetic (PK) model and to evaluate and quantify the influence of ritonavir on the PK of docetaxel. METHODS Data from two clinical trials were included in the data analysis, in which docetaxel (75 mg m,2 or 100 mg) had been administered intravenously or orally (10 mg or 100 mg) with or without co-administration of oral ritonavir (100 mg). Population modelling was performed using non-linear mixed effects modelling. A three-compartment model was used to describe the i.v. data. PK data after oral administration, with or without co-administration of ritonavir, were incorporated into the model. RESULTS Gut bioavailability of docetaxel increased approximately two-fold from 19 to 39% (CV 13%) with ritonavir co-administration. The hepatic extraction ratio and the elimination rate of docetaxel were best described by estimating the intrinsic clearance. Ritonavir was found to inhibit in a concentration dependent manner the intrinsic clearance of docetaxel, which was described by an inhibition constant of 0.028 µg ml,1 (CV 36%). A maximum inhibition of docetaxel clearance of more then 90% was reached. CONCLUSIONS A PK model describing both the PK of orally and intravenously administered docetaxel in combination with ritonavir, was successfully developed. Co-administration of ritonavir lead to increased oral absorption and reduced elimination rate of docetaxel. [source] NMR solution structure of a potent cyclic nonapeptide inhibitor of ICAM-1-mediated leukocyte adhesion produced by homologous amino acid substitutionCHEMICAL BIOLOGY & DRUG DESIGN, Issue 4 2004L.O. Sillerud Abstract:, We have previously described a disulfide-linked cyclic nonapeptide (inhibitory peptide-01, IP01), with the sequence CLLRMRSIC, which binds to intercellular adhesion molecule-1 (ICAM-1), and blocks binding to its counter-structure, the integrin ,L,2 (leukocyte functional antigen-1, LFA-1) (Sillerud et al., J. Peptide Res. 62, 2003: 97). We now report the optimization of this peptide by means of single homologous amino acid substitutions to yield a new peptide (IP02-K6; CLLRMKSAC) which shows an approximately sixfold improvement in inhibitory activity of multivalent leukocyte binding (inhibition constant for 50% inhibition, IC50 = 90 ,m) compared with IP01 (IC50 = 580 ,m). This improvement in activity gives IP02-K6 potent in vivo activity in a murine model of ischemia reperfusion injury (Merchant et al., Am. J. Physiol. Heart Circ. 284, 2003: H1260). In order to determine the structural features relevant to ICAM-1-binding, we have determined the structure of IP02-K6 using proton nuclear magnetic resonance (NMR) spectroscopy and restrained molecular modeling. In our previously reported study of solution models of IP01, we observed three interconverting conformations during low-temperature molecular dynamics simulation. In the present study, we find a single conformation of IP02-K6 similar to one of the previously found conformations of IP01 (family C). In particular, an R4-S7 , -turn is present in similar proportions in both conformation C of IP01 and in IP02-K6; this motif is important in binding to ICAM-1 because this turn enables the IP02-K6 backbone to drape over proline-36 on ICAM-1. The NMR-derived solution model of IP02-K6 was found to dock at the ,L,2 -binding site on ICAM-1 with no changes in peptide backbone conformation. This docking model displaced five of the 15 ,L,2 residues at the ICAM-1-binding site and provided a rationale for understanding the quantitative relationship between IP02-K6 structure and biologic activity. [source] Highly Potent and Selective Substrate Analogue Factor Xa Inhibitors Containing D -Homophenylalanine Analogues as P3 Residue: Part 2CHEMMEDCHEM, Issue 7 2007Anne Stürzebecher Dr. Abstract A series of highly potent substrate-analogue factor Xa inhibitors containing D -homophenylalanine analogues as the P3 residue has been identified by systematic optimization of a previously described inhibitor structure. An initial lead, benzylsulfonyl- d- hPhe-Gly-4-amidinobenzylamide (3), inhibits fXa with an inhibition constant of 6.0,nM. Most modifications of the P2 amino acid and P4 benzylsulfonyl group did not improve the affinity and selectivity of the compounds as fXa inhibitors. In contrast, further variation at the P3 position led to inhibitors with significantly enhanced potency and selectivity. Inhibitor 27, benzylsulfonyl- D -homo-2-pyridylalanyl(N-oxide)-Gly-4-amidinobenzylamide, inhibits fXa with a Ki value of 0.32,nM. The inhibitor has strong anticoagulant activity in plasma and doubles the activated partial thromboplastin time and prothrombin time at concentrations of 280,nM and 170,nM, respectively. Compound 27 inhibits the prothrombinase complex with an IC50 value of 5,nM and is approximately 50 times more potent than the reference inhibitor DX-9065a in this assay. [source] Batch kinetics and modelling of ethanolic fermentation of wheyINTERNATIONAL JOURNAL OF FOOD SCIENCE & TECHNOLOGY, Issue 6 2005Salman Zafar Summary The fermentation of whey by Kluyveromyces marxianus strain MTCC 1288 was studied using varying lactose concentrations at constant temperature and pH. The increase in substrate concentration up to a certain limit was accompanied by an increase in ethanol formation, for example, at a substrate concentration of 10 g L,1, the production of ethanol was 0.618 g L,1 whereas at 50 g L,1 it was 3.98 g L,1. However, an increase in lactose concentration to 100 g L,1 led to a drastic decrease in product formation and substrate utilization. The maximum ethanol yield was obtained with an initial lactose concentration of 50 g L,1. A method of batch kinetics was utilized to formulate a mathematical model using substrate and product inhibition constants. The model successfully simulated the batch kinetics observed at S0 = 10 and 50 g L,1 but failed in case of S0 = 100 g L,1 because of strong substrate inhibition. [source] REGULATION OF PHENYLALANINE AMMONIA-LYASE ENZYME IN ANNONA FRUIT: KINETIC CHARACTERISTICS AND INHIBITORY EFFECT OF AMMONIAJOURNAL OF FOOD BIOCHEMISTRY, Issue 2 2007R. MALDONADO ABSTRACT In this work, we analyzed the kinetic properties of phenylalanine ammonia-lyase (PAL) extracted from "cherimoya" (Annona cherimola Mill.) fruits ripened at ambient temperature (20C) and stored under several environmental conditions, including high CO2 levels (20%) and low temperature (6C). The effect of different ammonia-related compounds on cherimoya PAL activity was also evaluated. PAL exhibited two different Kmvalues for L-phenylalanine (L-Phe ) and negative substrate cooperativity, with Hill coefficient (napp) values reaching 0.64 and 0.71 for low temperature and high CO2 levels, respectively. The kinetic analysis revealed that ammonia produced mixed inhibition of PAL enzyme, with inhibition constants (Ki and Ki,) values of 0.57 ± 0.2 mM and 2.54 ± 0.2 mM. We propose that the regulation of PAL by ammonia inhibition and the negative cooperativity may be essential in adjusting the active phenylpropanoid metabolism in Annonas to the requirement of L-Phe and in consequence, to the carbon skeleton demand for other anabolic pathways. [source] Novel 3-benzoyl-2-piperazinylquinoxaline derivatives as potential antitumor agentsJOURNAL OF HETEROCYCLIC CHEMISTRY, Issue 3 2006Sandra Piras A series of new benzoylquinoxaline derivatives (7-26) was synthesized and evaluated for antitumor activity against a panel of 60 human cell lines at the NCI of Bethesda. Among the compounds which have passed the preliminary screening, compound 23 exhibited the best profile and growth inhibition activity at 100 - 10 ,M. The compounds were then tested towards a folate-dependent enzymes bio-library including Thymidylate synthases enzymes and human Dihydrofolate reductase at 10 ,M. The most of compounds exhibited a moderate inhibitory activity towards all or some of the enzymes tested with detectable inhibition constants (Ki) values in the range of 0.6-70 ,M. Compounds 21, 23, 24 showed Ki in the range of 10-38 ,M against both hDHFR and hTS. [source] Metabolic GHB precursor succinate binds to ,-hydroxybutyrate receptors: Characterization of human basal ganglia areas nucleus accumbens and globus pallidusJOURNAL OF NEUROSCIENCE RESEARCH, Issue 1 2006Tünde Molnár Abstract Binding of the metabolic ,-hydroxybutyrate (GHB) precursor succinate to NCS-382-sensitive [3H]GHB-labeled sites in crude synaptosomal or purified synaptic membrane fractions prepared from the human nucleus accumbens (NA), globus pallidus (GP) and rat forebrain has been shown. This site can be characterized by binding of ethyl hemisuccinate and gap-junction blockers, including carbenoxolone hemisuccinate and ,-GRA. There was no significant binding interaction between GABAB receptor ligands (CGP 55845, (R)-baclofen) and these [3H]GHB-labeled sites. GHB, NCS-382 and succinate binding profile of [3H]GHB-labeled sites in rat forebrain, human NA or GP synaptic membranes were similar. The synaptic fraction isolated from the rat forebrain was characterized by GHB binding inhibition constants: Ki,NCS-382 = 1.2 ± 0.2 ,M, Ki,GHB = 1.6 ± 0.3 ,M and Ki,SUCCINATE = 212 ± 66 ,M. In crude membranes containing mainly extrasynaptic membranes, distinct GHB and GABAB receptor sites were found in the NA. By contrast, extrasynaptic GABAB receptor sites of rat forebrain and GP were GHB- and succinate-sensitive, respectively. The heterogeneity of GABAB sites found in native membranes indicates GABAB receptor-dependent differences in GHB action. Based on these findings, we suggest that succinate (and possibly drugs available as succinate salt derivatives) can mimic some of the actions of GHB. © 2006 Wiley-Liss, Inc. [source] Modelling the effect of superatmospheric oxygen concentrations on in vitro mushroom PPO activity,JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, Issue 14 2006Perla A Gómez Abstract The kinetics of polyphenol oxidase (PPO, EC 1.14.18.1) with respect to oxygen concentrations from 5 to 100% using chlorogenic acid (CGA) as substrate was examined. In vitro mushroom PPO activity was determined by measuring the consumption of oxygen during the oxidation reaction. A differential Michaelis,Menten model was fitted to the obtained total depletion curves. The product concentration as well as the concentration of oxygen had a clear inhibitory effect on the reaction rate. However, the inhibitory effect of oxygen was more evident at low product concentration. A linear mixed inhibition model that considered both the product (oxidised CGA) and oxygen as inhibitors was developed. A model with the product as a competitive inhibitor and oxygen as an uncompetitive inhibitor was the most appropriate to explain the reaction kinetics. The values of the inhibition constants calculated from the model were 0.0032 mmol L,1 for Km (Michaelis,Menten constant related to oxygen), 0.023 mmol L,1 for Kmc (constant for competitive inhibition due to the product), 1.630 mmol L,1 for Kmu (constant for uncompetitive inhibition due to oxygen) and 1.77 × 10,4 mmol L,1 s,1 for Vmax (maximum reaction rate). The results indicate that superatmospheric oxygen concentrations could be effective in preventing enzymatic browning by PPO. Copyright © 2006 Society of Chemical Industry [source] Energy-dependent degradation: Linkage between ClpX-catalyzed nucleotide hydrolysis and protein-substrate processingPROTEIN SCIENCE, Issue 5 2003Randall E. Burton Abstract ClpX requires ATP to unfold protein substrates and translocate them into the proteolytic chamber of ClpP for degradation. The steady-state parameters for hydrolysis of ATP and ATP,S by ClpX were measured with different protein partners and the kinetics of degradation of ssrA-tagged substrates were determined with both nucleotides. ClpX hydrolyzed ATP,S to ADP and thiophosphate at a rate (6/min) significantly slower than ATP hydrolysis (140/min), but the hydrolysis of both nucleotides was increased by ssrA-tagged substrates and decreased by ClpP. KM and kcat for hydrolysis of ATP and ATP,S were linearly correlated over a 200-fold range, suggesting that protein partners largely affect kcat rather than nucleotide binding, indicating that most bound ATP leaves the enzyme by hydrolysis rather than dissociation, and placing an upper limit of ,15 ,M on KD for both nucleotides. Competition studies with ClpX and fluorescently labeled ADP gave inhibition constants for ATP,S (,2 ,M) and ADP (,3 ,M) under the reaction conditions used for steady-state kinetics. In the absence of Mg2+, where hydrolysis does not occur, the inhibition constant for ATP (,55 ,M) was weaker but very similar to the value for ATP,S (,45 ,M). Compared with ATP, ATP,S supported slow but roughly comparable rates of ClpXP degradation for two Arc-ssrA substrates and denatured GFP-ssrA, but not of native GFP-ssrA. These results show that the processing of protein substrates by ClpX is closely coupled to the maximum rate of nucleotide hydrolysis. [source] Novel ferrocenyl phosphonate derivatives.APPLIED ORGANOMETALLIC CHEMISTRY, Issue 10 2010Inhibition of serine hydrolases by ferrocene azaphosphonates Abstract Owing to their unique properties, ferrocene compounds are gaining increasing interest for biological applications, particularly as enzyme inhibitors. Phosphonate derivatives including a ferrocenyl moiety were synthesized by reaction of dimethyl- and diphenylphosphite with ferrocenyl methyl maleimide. The ferrocenyl diphenyl phosphonate complex was characterized by X-ray diffraction. The ability of these organometallic compounds to inhibit the enzymatic activity of the serine esterases acetyl- and butyrylcholinesterase was investigated. It appeared that the new ferrocenyl phosphonates inhibited both enzymes by competitive, mixed or non competitve mechanisms with inhibition constants in the range 35,1000 µM. Both compounds also behave as slow time-dependent inactivators of butyrylcholinesterase. The presence of the ferrocenyl entity seems then to have a dramatic effect on the biochemical behavior of the systems. Copyright © 2010 John Wiley & Sons, Ltd. [source] Biosynthesis reaction mechanism and kinetics of deoxynucleoside triphosphates, dATP and dGTPBIOTECHNOLOGY & BIOENGINEERING, Issue 4 2005Jie Bao Abstract The enzyme reaction mechanism and kinetics for biosyntheses of deoxyadenosine triphosphate (dATP) and deoxyguanosine triphosphate (dGTP) from the corresponding deoxyadenosine diphosphate (dADP) and deoxyguanosine diphosphate (dGDP) catalyzed by pyruvate kinase were studied. A kinetic model for this synthetic reaction was developed based on a Bi-Bi random rapid equilibrium mechanism. Kinetic constants involved in this pyruvate kinase catalyzed phosphorylation reactions of deoxynucleoside diphosphates including the maximum reaction velocity, Michaelis-Menten constants, and inhibition constants for dATP and dGTP biosyntheses were experimentally determined. These kinetic constants for dATP and dGTP biosyntheses are of the same order of magnitude but significantly different between the two reactions. Kinetic constants involved in ATP and GTP biosyntheses as reported in literature are about one order of magnitude different from those involved in dATP and dGTP biosyntheses. This enzyme reaction requires Mg2+ ion and the optimal Mg2+ concentration was also determined. The experimental results showed a very good agreement with the simulation results obtained from the kinetic model developed. This kinetic model can be applied to the practical application of a pyruvate kinase reaction system for production of dATP and dGTP. There is a significant advantage of using enzymatic biosyntheses of dATP and dGTP as compared to the chemical method that has been in commercial use. © 2005 Wiley Periodicals, Inc. [source] Carbonic Anhydrase Inhibitors: Inhibition of Cytosolic Carbonic Anhydrase Isozymes II and VII with Simple Aromatic Sulfonamides and Some Azo DyesCHEMICAL BIOLOGY & DRUG DESIGN, Issue 2 2009Fabrizio Carta Several substituted benzenesulfonamides were synthesized by various pathways starting from sulfanilamide. The sulfanilamide diazonium salt was reacted with copper (I) halides, potassium iodide and/or aromatic derivatives, leading to 4-halogeno-, and 4-hydroxy-benzenesulfonamides as well as diazo dyes incorporating sulfamoyl moieties. These sulfonamides were assayed as inhibitors of two physiologically relevant isoforms of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1), i.e., the cytosolic CA II (ubiquitous), and CA VII (brain-specific enzyme). Good CA inhibitory activity was detected for some of these derivatives, with inhibition constants (Ki) in the range of 17.5,863 nm against CA II; and 30,4200 nm against CA VII. [source] 3-Fluoro-2,4-dioxa-3-phosphadecalins as Inhibitors of Acetylcholinesterase.CHEMISTRY & BIODIVERSITY, Issue 3 2009A Reappraisal of Kinetic Mechanisms, Diagnostic Methods Abstract A systematic survey of the acetylcholine-mimetic 2,4-dioxa-3-phosphadecalins as irreversible inhibitors of acetylcholinesterase revealed hitherto overlooked properties as far as the kinetic mechanisms of interaction are concerned. As a support to past and future work in this field, we describe the kinetics of eight reaction schemes that may be found in irreversible enzyme modification and compare them with two mechanism of reversible, slow-binding inhibition. The relevant kinetic equations and their associated graphical representations are given for all mechanisms, and concrete examples illustrate their practical use. Since irreversible inhibition is a time-dependent phenomenon, kinetic analysis is greatly facilitated by fitting the appropriate integrated rate equations to reaction-progress curves by nonlinear regression. This primary scrutiny provides kinetic parameters that are indispensable tools for diagnosing the kinetic mechanism and for calculating inhibition constants. Numerical integration of sets of differential equations is an additional useful investigation tool in critical situations, e.g., when inhibitors are unstable and/or act as irreversible modifiers only temporarily. [source] Nanomolar Competitive Inhibitors of Mycobacterium tuberculosis and Streptomyces coelicolor Type,II DehydroquinaseCHEMMEDCHEM, Issue 2 2007Verónica F. Abstract Isomeric nitrophenyl and heterocyclic analogues of the known inhibitor (1S,3R,4R)-1,3,4-trihydroxy-5-cyclohexene-1-carboxylic acid have been synthesized and tested as inhibitors of M.,tuberculosis and S.,coelicolor type,II dehydroquinase, the third enzyme of the shikimic acid pathway. The target compounds were synthesized by a combination of Suzuki and Sonogashira cross-coupling and copper(I)-catalyzed 2,3-dipolar cycloaddition reactions from a common vinyl triflate intermediate. These studies showed that a para -nitrophenyl derivative is almost 20-fold more potent as a competitive inhibitor against the S.,coelicolor enzyme than that of M.,tuberculosis. The opposite results were obtained with the meta isomer. Five of the bicyclic analogues reported herein proved to be potent competitive inhibitors of S.,coelicolor dehydroquinase, with inhibition constants in the low nanomolar range (4,30,nM). These derivatives are also competitive inhibitors of the M.,tuberculosis enzyme, but with lower affinities. The most potent inhibitor against the S.,coelicolor enzyme, a 6-benzothiophenyl derivative, has a Ki value of 4,nM,over 2000-fold more potent than the best previously known inhibitor, (1R,4R,5R)-1,5-dihydroxy-4-(2-nitrophenyl)cyclohex-2-en-1-carboxylic acid (8,,M), making it the most potent known inhibitor against any dehydroquinase. The binding modes of the analogues in the active site of the S.,coelicolor enzyme (GOLD,3.0.1), suggest a key , -stacking interaction between the aromatic rings and Tyr,28, a residue that has been identified as essential for enzyme activity. [source] | ||||||||||||||||||||||||||||